| Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America PG Pappas, CA Kauffman, DR Andes, CJ Clancy, KA Marr, ... Clinical infectious diseases 62 (4), e1-e50, 2016 | 4221 | 2016 |
| Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America PG Pappas, CA Kauffman, D Andes, DK Benjamin Jr, TF Calandra, ... Clinical infectious diseases: an official publication of the Infectious …, 2009 | 3888 | 2009 |
| Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever TJ Walsh, P Pappas, DJ Winston, HM Lazarus, F Petersen, J Raffalli, ... New England Journal of Medicine 346 (4), 225-234, 2002 | 1233 | 2002 |
| Anidulafungin versus fluconazole for invasive candidiasis AC Reboli, C Rotstein, PG Pappas, SW Chapman, DH Kett, D Kumar, ... New England Journal of Medicine 356 (24), 2472-2482, 2007 | 1071 | 2007 |
| Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials DR Andes, N Safdar, JW Baddley, G Playford, AC Reboli, JH Rex, ... Clinical infectious diseases 54 (8), 1110-1122, 2012 | 890 | 2012 |
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases TJ Walsh, JW Hiemenz, NL Seibel, JR Perfect, G Horwith, L Lee, JL Silber, ... Clinical Infectious Diseases 26 (6), 1383-1396, 1998 | 791 | 1998 |
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis PG Pappas, CMF Rotstein, RF Betts, M Nucci, D Talwar, JJ De Waele, ... Clinical infectious diseases 45 (7), 883-893, 2007 | 768 | 2007 |
| Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who … M Boogaerts, DJ Winston, EJ Bow, G Garber, AC Reboli, AP Schwarer, ... Annals of internal medicine 135 (6), 412-422, 2001 | 491 | 2001 |
| Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008 MA Pfaller, DR Andes, DJ Diekema, DL Horn, AC Reboli, C Rotstein, ... PloS one 9 (7), e101510, 2014 | 484 | 2014 |
| Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America PG Pappas, CA Kauffman, DR Andes, CJ Clancy, KA Marr, ... Clinical Infectious Diseases 62 (4), 409-417, 2016 | 378 | 2016 |
| Erysipelothrix rhusiopathiae: an occupational pathogen AC Reboli, WE Farrar Clinical microbiology reviews 2 (4), 354-359, 1989 | 302 | 1989 |
| Recombinant Interferon-γlb as adjunctive therapy for AIDS-related acute cryptococcal meningitis PG Pappas, B Bustamante, E Ticona, RJ Hamill, PC Johnson, A Reboli, ... The Journal of infectious diseases 189 (12), 2185-2191, 2004 | 239 | 2004 |
| Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia DS Krause, J Reinhardt, JA Vazquez, A Reboli, BP Goldstein, M Wible, ... Antimicrobial agents and chemotherapy 48 (6), 2021-2024, 2004 | 210 | 2004 |
| Amphotericin B lipid complex in pediatric patients with invasive fungal infections TJ Walsh, NL Seibel, C Arndt, RE Harris, MJ Dinubile, A Reboli, ... The Pediatric infectious disease journal 18 (8), 702-708, 1999 | 204 | 1999 |
| MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the … L Ostrosky-Zeichner, S Shoham, J Vazquez, A Reboli, R Betts, MA Barron, ... Clinical infectious diseases 58 (9), 1219-1226, 2014 | 180 | 2014 |
| Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention … TJ Walsh, HC Standiford, AC Reboli, JF John, ME Mulligan, BS Ribner, ... Antimicrobial agents and chemotherapy 37 (6), 1334-1342, 1993 | 167 | 1993 |
| Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit L Ostrosky‐Zeichner, PG Pappas, S Shoham, A Reboli, MA Barron, ... Mycoses 54 (1), 46-51, 2011 | 151 | 2011 |
| Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel CJ Clancy, PG Pappas, J Vazquez, MA Judson, DP Kontoyiannis, ... Clinical Infectious Diseases 66 (11), 1678-1686, 2018 | 150 | 2018 |
| Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for … DH Kett, AF Shorr, AC Reboli, AL Reisman, P Biswas, HT Schlamm Critical care 15, 1-7, 2011 | 127 | 2011 |
| Discrimination of epidemic and sporadic isolates of Acinetobacter baumannii by repetitive element PCR-mediated DNA fingerprinting AC Reboli, ED Houston, JS Monteforte, CA Wood, RJ Hamill Journal of Clinical Microbiology 32 (11), 2635-2640, 1994 | 126 | 1994 |
peter pappasUniversity of Alabama at BirminghamVerified email at uab.edu
